Shingles Vaccine Market Size & Growth Forecast 2026–2035, By Segments (Vaccine Type, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Shingles Vaccine Market size was worth USD 5.42 Billion in 2025 and is expected to grow at a 15.2% CAGR between 2026 and 2035, reaching USD 22.31 Billion by 2035. The industry revenue for 2026 is assessed at USD 6.15 billion.

• Base Year Value (2025): USD 5.42 Billion
• CAGR (2026-2035): 15.2%
• Forecast Year Value (2035): USD 22.31 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Shingles Vaccine Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads with 60.39% share due to strong vaccine access, established adult immunization programs, reimbursement support, and pharmacy-based distribution channels enabling broad uptake.
  • Asia Pacific is expanding at 17.02% CAGR driven by improving adult vaccination awareness, expanding healthcare access, and strengthening immunization infrastructure across large aging populations.

• Segment Momentum:

  • Shingrix accounted for 89.43% of the market in 2025 due to its strong presence in vaccination programs, established prescribing practices, and well-developed commercial distribution and procurement channels.
  • Live Attenuated Vaccine is the fastest-growing vaccine type as expanding regional immunization programs and favorable local procurement patterns create new opportunities for broader market adoption.

• Market Expansion Drivers:

  • Expanding elderly population increasing demand for preventive shingles immunization programs globally.
  • Advancements in recombinant vaccine technology improving efficacy and driving broader clinical adoption.
  • Government-led adult vaccination initiatives expanding coverage in emerging healthcare systems and markets.

• Leading Market Participants:

  Major companies in the shingles vaccine market include GlaxoSmithKline plc (United Kingdom), Merck & Co. Inc. (United States), Pfizer Inc. (United States), SK bioscience Co. Ltd. (South Korea), Green Cross Corporation (South Korea), Geneone Life Science Inc. (South Korea), CanSino Biologics Inc. (China), Moderna Inc. (United States), Vaccitech plc (United Kingdom), BioNTech SE (Germany).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 5.42 Billion
  • 2026 Market Size: USD 15.2 billion
  • Projected Market Size: USD 22.31 Billion by 2035
  • Growth Forecasts: 15.2% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Recombinant Vaccine (Vaccine Type) | Shingrix (Product)
  • Emerging Opportunity Segment: Live Attenuated Vaccine (Vaccine Type) | SKYZoster (Product)

Market Growth Drivers and Industry Trends

Expanding elderly population increasing demand for preventive shingles immunization programs globally

As the share of older adults rises, healthcare systems and providers are placing greater emphasis on prevention for age-associated infectious conditions, which is directly increasing demand for the shingles vaccine market. Shingles risk increases with age as immune function declines, so vaccination is increasingly being built into routine adult immunization schedules, geriatric care pathways, and pharmacy-based preventive health programs. This demographic shift also changes purchasing behavior at the system level, with hospitals, clinics, and public health agencies planning larger vaccine volumes and expanding outreach to aging populations, encouraging market growth through more consistent and recurring immunization demand.

Advancements in recombinant vaccine technology improving efficacy and driving broader clinical adoption

Improvements in recombinant vaccine technology are influencing market adoption by giving clinicians and immunization programs a stronger efficacy profile to justify adult shingles vaccination, especially for older and higher-risk populations. In the shingles vaccine market, better-performing recombinant formulations strengthen physician confidence, shape treatment recommendations, and support inclusion in clinical protocols where long-term protection and reduced disease burden are central considerations. That shift affects procurement and prescribing in practical terms, as healthcare providers and payers are more willing to support vaccines that align with preventive care objectives and deliver clearer value in adult immunization strategies.

Government-led adult vaccination initiatives expanding coverage in emerging healthcare systems and markets

Public-sector vaccination initiatives are increasing market presence by making adult immunization more visible, organized, and accessible in healthcare systems where shingles prevention has historically received limited attention. In the shingles vaccine market, government-backed programs often translate into formal recommendations, national procurement channels, reimbursement support, and integration into primary care delivery, all of which reduce access barriers for eligible adults. As emerging healthcare systems expand their preventive care infrastructure, these policies also influence provider behavior by normalizing adult vaccination as part of routine care rather than a discretionary intervention.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Expanding elderly population increasing demand for preventive shingles immunization programs globally	2.60%	High	North America, Europe	High	Near Term
Advancements in recombinant vaccine technology improving efficacy and driving broader clinical adoption	2.30%	High	North America, Asia Pacific	High	Mid Term
Government-led adult vaccination initiatives expanding coverage in emerging healthcare systems and markets	2.00%	High	Asia Pacific, Latin America	Emerging	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading regional share of the shingles vaccine market in 2025, accounting for 60.39% share. This position is underpinned by broad vaccine access through established healthcare delivery networks, strong adult immunization uptake, and routine use of preventive care in clinical practice. Market activity is further bolstered by high awareness of age-related disease prevention and the presence of structured reimbursement and pharmacy-based vaccination channels, which make adult shingles vaccination easier to recommend, dispense, and administer at scale.

Asia Pacific is projected to expand at a 17.02% CAGR over the forecast period in the shingles vaccine market, driven by improving adult vaccination awareness and wider healthcare access across major population centers. Growth is being accelerated by the practical expansion of immunization infrastructure, rising engagement with preventive healthcare, and increasing diagnosis and management of aging-related conditions through formal healthcare systems. As more patients enter organized care pathways and vaccine availability improves, adoption is gaining momentum across the region.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Emerging	Nascent
Cost-Sensitive Region	Low	Medium	Low	High	High
Regulatory Environment	Supportive	Neutral	Restrictive	Neutral	Neutral
Demand Drivers	Strong	Moderate	Strong	Moderate	Weak
Development Stage	Developed	Developing	Developed	Emerging	Emerging
Adoption Rate	High	Medium	High	Low	Low
New Entrants / Startups	Dense	Moderate	Dense	Sparse	Sparse
Macro Indicators	Strong	Stable	Stable	Weak	Weak

Key Country Insights

United States

Adult Immunization Expansion

The U.S. shingles vaccine market emphasizes expanding adult immunization through preventive healthcare initiatives and broad healthcare provider engagement. Vaccination programs increasingly focus on improving awareness among eligible adults while strengthening access through pharmacies and healthcare networks.

Japan

Aging Population Protection

Japan prioritizes shingles vaccination as part of broader efforts to reduce disease burden among its aging population. Public health initiatives and healthcare providers continue encouraging vaccination uptake through improved awareness and preventive healthcare engagement.

South Korea

Preventive Vaccination Uptake

South Korea continues expanding shingles vaccination through preventive healthcare initiatives targeting adults at elevated risk. Healthcare providers focus on increasing awareness, improving patient education, and incorporating vaccination into broader adult immunization practices.

Germany

Preventive Healthcare Alignment

Germany supports shingles vaccination through established preventive healthcare practices and recommendations for older adults. Healthcare providers continue promoting vaccination awareness while integrating immunization into routine preventive care and primary healthcare services.

France

Healthcare Access Reinforcement

France strengthens shingles vaccination through coordinated healthcare services and preventive care strategies for eligible adults. The market supports greater physician engagement and improved patient awareness to encourage broader vaccination participation.

Italy

Community Immunization Focus

Italy promotes shingles vaccination through regional healthcare programs and preventive immunization initiatives aimed at older adults. Healthcare organizations continue emphasizing patient education and accessible vaccination pathways to support consistent immunization practices.

Segment Leadership and Growth Trends

  Vaccine Type Segment Analysis: Recombinant Vaccine (Largest Segment) vs Live Attenuated Vaccine (Fastest-Growing Segment)

Recombinant Vaccine held the dominant position in the shingles vaccine market in 2025, accounting for an 89.43% share. Its leadership is maintained through strong alignment with current immunization preferences, particularly where providers and public health programs prioritize broader adult use and dependable deployment across aging populations. Within the shingles vaccine market, this segment benefits from being the established choice in routine prevention pathways, which helps preserve purchasing continuity and physician familiarity.

Live Attenuated Vaccine is emerging as the fastest-growing segment in the shingles vaccine market as manufacturers and healthcare systems seek to expand access across varied regional product landscapes. Its momentum is underpinned by practical uptake opportunities in settings where existing vaccination infrastructure, product availability, or local procurement patterns favor this format over alternatives. Relative to more entrenched options, growth is being driven less by category dominance and more by incremental adoption in markets that are still broadening shingles immunization coverage.

Product Segment Analysis: Shingrix (Largest Segment) vs SKYZoster (Fastest-Growing Segment)

In 2025, Shingrix led the shingles vaccine market with an 89.43% share, reflecting its entrenched role in commercial supply channels and adult vaccination programs. The product maintains its leadership because demand in the market is concentrated around solutions already embedded in prescribing practices, distribution systems, and preventive care recommendations. This creates a practical advantage in ongoing procurement and administration, reinforcing Shingrix as the dominant product segment.

SKYZoster is the fastest-growing product segment in the shingles vaccine market, gaining traction as healthcare providers and regional buyers widen their product mix to support broader immunization reach. Its growth is tied to expansion opportunities where local availability, procurement flexibility, or market entry dynamics allow it to capture new demand more quickly than established products. Compared with the leading alternative, SKYZoster is benefiting from adoption in less saturated pockets of the market rather than from existing scale.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Vaccine Type	Recombinant Vaccine, Live Attenuated Vaccine	Recombinant Vaccine	Live Attenuated Vaccine
Product	Shingrix, Zostavax, SKYZoster	Shingrix	SKYZoster

Competitive Landscape and Market Positioning

Top players in the shingles vaccine market:

1. GlaxoSmithKline plc (United Kingdom)

2. Merck & Co. Inc. (United States)

3. Pfizer Inc. (United States)

4. SK bioscience Co. Ltd. (South Korea)

5. Green Cross Corporation (South Korea)

6. Geneone Life Science Inc. (South Korea)

7. CanSino Biologics Inc. (China)

8. Moderna Inc. (United States)

9. Vaccitech plc (United Kingdom)

10. BioNTech SE (Germany)

The shingles vaccine market is expanding due to increasing focus on preventive healthcare and aging population needs. The shingles vaccine market is witnessing innovation in next-generation immunization technologies. Continuous research collaboration is improving vaccine efficacy and protection duration.

Industry Development/News

Company Name	Date	Key Development
Eli Lilly	Feb-26	Eli Lilly executed definitive agreements to acquire Curevo, LimmaTech, and Vaccine Company in an aggregate transaction valued up to $3.8 billion. The multi-asset acquisition significantly expands Eli Lilly's pipeline across viral and bacterial pathogens, explicitly integrating Curevo's specialized assets to accelerate corporate entry and research capabilities within the next-generation shingles prevention market.
Sanofi	Feb-26	Sanofi reached an agreement to acquire Dynavax Technologies for approximately $2.2 billion, absorbing its commercial immunization portfolio alongside Z-1018, an investigational Phase 1/2 shingles vaccine candidate. The strategic transaction accelerates Sanofi's competitive positioning in adult vaccinology, providing a direct pipeline entry point to challenge established market leaders in herpes zoster prevention.
Curevo Vaccine	Feb-26	Curevo Vaccine secured $110 million in Series B venture financing led by Medicxi, with co-investment from OrbiMed, HBM Healthcare Investments, and Sanofi Ventures. The capital infusion is strategically earmarked to fund the advanced clinical expansion and regulatory development of amezosvatein, the company's leading investigational shingles vaccine candidate.
AIM Vaccine Co., Ltd.	Mar-25	AIM Vaccine Co., Ltd. secured investigational clinical trial approval from the U.S. Food and Drug Administration for its independently developed mRNA shingles vaccine candidate. The regulatory clearance allows the company to initiate human trials within the United States, marking a critical operational milestone for mRNA platform validation in the competitive shingles prevention landscape.
Dynavax Technologies Corporation	Jun-24	Dynavax Technologies Corporation initiated patient dosing in its Phase 1/2 clinical trial evaluating the safety, tolerability, and immunogenicity of its investigational shingles vaccine candidate, Z-1018. This clinical milestone marks the early-stage commercial development of an alternative adjuvant-based therapeutic regimen designed to prevent herpes zoster reactivations.
EuBiologics	Feb-26	EuBiologics disclosed positive interim data from its Phase 1 clinical trial of the EuHZV shingles vaccine candidate, demonstrating safety and immunogenicity profiles comparable to an active control vaccine. The clinical results establish a viable baseline to advance the candidate into larger efficacy trials, positioning the firm to contest the global shingles market.
SK bioscience	Jan-23	SK bioscience obtained Biologics License Application approval from Malaysia’s National Pharmaceutical Regulatory Agency for its shingles vaccine, SKYZoster. This regulatory clearance marks the product’s second international market entry following its initial approval in Thailand, expanding the manufacturer's geographic footprint and commercial distribution network across Southeast Asia.
GlaxoSmithKline (GSK)	Feb-26	GlaxoSmithKline expanded the commercial footprint of its recombinant zoster vaccine, Shingrix, by launching the product in Malaysia. The geographic expansion broadens preventative healthcare access for adults aged 50 and older or those at elevated risk, reinforcing the company's dominant global market share in shingles prevention.
GlaxoSmithKline (GSK)	Mar-25	GlaxoSmithKline formed a specialized research coalition with the UK Dementia Research Institute and Health Data Research UK to execute a population-level health data study. The scientific initiative investigates a potential statistical correlation between Shingrix vaccination and reduced dementia incidence, potentially generating unique clinical differentiation and a new marketing paradigm for the asset.
SK bioscience	Feb-26	SK bioscience reorganized its operational focus to scale its commercial shingles vaccine portfolio, aiming to capture global market share unaddressed due to recent competitor product withdrawals. The defensive repositioning optimizes supply chain and manufacturing capabilities to align with rising seasonal demands for adult immunizations.